Healthcare provider profile · identity verified

Gary X. Heck, DO

Family Practice · LINDENWOLD, NJ · NPI 1316984180

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	488	140
Metoprolol Succinate	Metoprolol Succinate	313	85
Amlodipine Besylate	Amlodipine Besylate	264	78
Lisinopril	Lisinopril	224	66
Levothyroxine Sodium	Levothyroxine Sodium	209	50
Omeprazole	Omeprazole	184	51
Simvastatin	Simvastatin	167	50
Glimepiride	Glimepiride	135	35
Metformin Hcl	Metformin Hcl	135	37
Montelukast Sodium	Montelukast Sodium	115	31
Pantoprazole Sodium	Pantoprazole Sodium	104	27
Jardiance	Empagliflozin	96	26
Lorazepam	Lorazepam	91	24
Hydrochlorothiazide	Hydrochlorothiazide	90	28
Duloxetine Hcl	Duloxetine Hcl	89	25
Metformin Hcl Er	Metformin Hcl	88	27
Ozempic	Semaglutide	76	15
Gabapentin	Gabapentin	75	16
Rosuvastatin Calcium	Rosuvastatin Calcium	75	23
Losartan Potassium	Losartan Potassium	73	25
Furosemide	Furosemide	72	23
Ezetimibe	Ezetimibe	71	24
Paroxetine Hcl	Paroxetine Hcl	63	19
Pravastatin Sodium	Pravastatin Sodium	61	13
Albuterol Sulfate Hfa	Albuterol Sulfate	57	17
Farxiga	Dapagliflozin Propanediol	57	16
Esomeprazole Magnesium	Esomeprazole Magnesium	54	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	53	15
Buspirone Hcl	Buspirone Hcl	50	16
Tramadol Hcl	Tramadol Hcl	50	11
Acetaminophen-Codeine	Acetaminophen With Codeine	46	13
Clopidogrel	Clopidogrel Bisulfate	46	14
Tamsulosin Hcl	Tamsulosin Hcl	45	14
Fluticasone Propionate	Fluticasone Propionate	44	16
Metoprolol Tartrate	Metoprolol Tartrate	44	11
Methylprednisolone	Methylprednisolone	43	36
Sertraline Hcl	Sertraline Hcl	40	12
Pioglitazone Hcl	Pioglitazone Hcl	39	13
Telmisartan	Telmisartan	34	suppressed
Alprazolam	Alprazolam	32	suppressed
Allopurinol	Allopurinol	30	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	29	16
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	28	suppressed
Clonazepam	Clonazepam	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Eliquis	Apixaban	27	suppressed
Myrbetriq	Mirabegron	27	suppressed
Valsartan	Valsartan	27	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	26	suppressed
Fenofibrate	Fenofibrate	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Bydureon Bcise	Exenatide Microspheres	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	12
Atenolol	Atenolol	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Finasteride	Finasteride	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Cephalexin	Cephalexin	13	suppressed
Famotidine	Famotidine	13	suppressed
Temazepam	Temazepam	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Diazepam	Diazepam	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error